Founded in 1986 by Mr. P. V. Ramprasad Reddy, Mr. K. Nithyananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born of a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and anti-biotics, among others.
此公司進入各市場的次序 — 由最舊至最新
Business Development Manager
印度股市收高，製藥股受關注
註冊以查看完整訊號動態
AUROBINDO PHARMA LTD 的國際擴張與競爭對手的比較
AUROBINDO PHARMA LTD你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 AUROBINDO PHARMA LTD你 | 0 | 0 | 0% | 0 | 31 |
Business Development Manager
查看招聘Ho Chi Minh City, Vietnam · 5個月前
Interesting Job Opportunity: Eugia Pharma - Manager - Production QMS
查看招聘Naidupeta, Andhra Pradesh, India · 5個月前
Assistant Manager
查看招聘Naidupeta, Andhra Pradesh, India · 6個月前
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
包括SBI、ITC、Airtel、Hero MotoCorp、Britannia和Trent在內的六家Nifty 50公司將於週四公佈第三季度業績。分析師提供了這些公司的收入和利潤預估。
IIFL金融、Piramal企業、Dalmia Bharat等是關鍵觀察股。IIFL批准發行NCD，Piramal面臨GST需求，Aditya Birla房地產推出成功項目。
包括IndiGo、Aurobindo Pharma和Dabur India在內的幾家印度公司預計將因各種公司發展和財務業績而出現重大市場行動。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 AUROBINDO PHARMA LTD 業務、市場及增長訊號的快速解答。
